News Releases

DateTitle 
09/03/21

Company to File Amended Plan of Reorganization to Incorporate Terms

Company Anticipates Commencing its Confirmation Hearing in September 2021

DUBLIN , Sept. 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached
Printer Friendly Version
09/02/21
Analysis from the largest known, ongoing, retrospective, explorative, single-arm, pan-European multicenter study of ECP in heart transplant patients suggests potential for ECP in the treatment of acute cellular rejection, antibody mediated rejection and prevention of rejection – Company awards
Printer Friendly Version
07/07/21
- First publication of full data set shows use of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) eliminated autografting in 96% of burn sites treated with StrataGraft, and 83.1% of patients achieved durable wound closure of the StrataGraft
Printer Friendly Version
07/01/21
-- Along with a Sarcoidosis Expert Panel Consensus Statement previously published in European Respiratory Review, the ERS guidelines support the use of Acthar Gel in the management of certain patients with symptomatic pulmonary sarcoidosis -- -- Guidelines are the first ERS-issued evidence-based
Printer Friendly Version
06/15/21
-- First approved donor site-free alternative to autograft for deep partial-thickness burns designed to handle like an autograft and support body's own ability to heal -- -- Clinical trials of StrataGraft demonstrated autograft sparing and durable wound closure by 3 months in adults with deep
Printer Friendly Version
05/03/21
‒ Phase 4 open-label study showed clinically important improvement in the patient-reported Impact of Dry Eye on Everyday Life (IDEEL) symptom bother score, the study's primary outcome measure - DUBLIN , May 3, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical
Printer Friendly Version
04/30/21
- Full results presented for Phase 4 observational registry, which ended early upon achievement of statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim analysis - DUBLIN , April 30, 2021 /PRNewswire/ -- Mallinckrodt plc
Printer Friendly Version
03/29/21
-- Mallinckrodt's Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response -- -- Hobart, New York site honored for fourth consecutive year, recognized for Operational Excellence Leadership in 2021 -- ST.
Printer Friendly Version
03/24/21
̶ Tanya Hill and Megan Roberts recognized as HBA Luminary and Rising Star for 2021 ̶   DUBLIN, March 24, 2021 – Mallinckrodt plc, a global biopharmaceutical company, today announced that employees Tanya Hill, Executive Director, Commercial Strategy and Brand Planning, will be honored as a Luminary;
Printer Friendly Version
03/22/21
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Approves Updated Acthar® Gel (Repository Corticotropin Injection) Label DUBLIN – March 22, 2021 –  Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved
Printer Friendly Version
03/19/21
-- Rich diversity of cutting-edge ECP science represented in Mallinckrodt’s 2021 research award -- Dublin, Ireland, March 19, 2021 – A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells has won Mallinckrodt plc’s 2021 Advances
Printer Friendly Version
03/10/21
DUBLIN , March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien term lenders holding approximately $1.3 billion of its outstanding First Lien Term Loans (the "First Lien Term
Printer Friendly Version
03/04/21
-- CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis -- DUBLIN , March 4, 2021 /PRNewswire/ -- Mallinckrodt plc , a global biopharmaceutical company, today
Printer Friendly Version
02/12/21
DUBLIN , Feb. 12, 2021 /PRNewswire/ --  Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application (BLA) for
Printer Friendly Version
01/29/21
Company earns 100 on the Human Rights Campaign Foundation’s annual assessment of LGBTQ workplace equality DUBLIN – January 29, 2021 – Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2021 Corporate
Printer Friendly Version
01/27/21
  DUBLIN – January 27, 2021 –  Mallinckrodt plc , a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft versus
Printer Friendly Version